224 related articles for article (PubMed ID: 15561826)
1. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
2. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
6. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.
Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627
[TBL] [Abstract][Full Text] [Related]
7. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
9. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations.
Klein JL; Brown TJ; French GL
Antimicrob Agents Chemother; 2001 Nov; 45(11):3056-8. PubMed ID: 11600355
[TBL] [Abstract][Full Text] [Related]
10. [Multicenter evaluation of a newly developed microdilution test, brothMIC NTM to determine minimum inhibitory concentrations of antimicrobial agents for nontuberculous mycobacteria].
Yamane N; Onaga S; Saitoh H; Toyoshima S; Shimojima M; Kawahara S; Takashima T; Yamashita T
Rinsho Byori; 2002 Apr; 50(4):381-91. PubMed ID: 12014018
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B
Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
[TBL] [Abstract][Full Text] [Related]
13. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Bhusal Y; Shiohira CM; Yamane N
Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Rodriguez Díaz JC; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
[TBL] [Abstract][Full Text] [Related]
15. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
Hombach M; Somoskövi A; Hömke R; Ritter C; Böttger EC
Int J Med Microbiol; 2013 Jul; 303(5):270-6. PubMed ID: 23689069
[TBL] [Abstract][Full Text] [Related]
16. Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil.
de Carvalho LD; de Queiroz Mello FC; Redner P; Campos CED; de Souza Caldas PC; da Silva Lourenço MC; Ramos JP
J Glob Antimicrob Resist; 2019 Dec; 19():228-230. PubMed ID: 31100506
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system.
Royo P; Martín-Casabona N; Martínez E; Andonegui M
Int J Tuberc Lung Dis; 1999 Apr; 3(4):349-53. PubMed ID: 10206507
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
Tsukamura M
Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
[TBL] [Abstract][Full Text] [Related]
19. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
20. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
